Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominique Roulot

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Hepatology (Baltimore, Md.)|June 28, 2016
Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir)Nathalie Ganne-Carrié, Richard Layese, Valérie Bourcier, et al.
Hepatology (Baltimore, Md.)|February 14, 2015
Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)Jean-Claude Trinchet, Valérie Bourcier, Cendrine Chaffaut, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|January 22, 2011
Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS studyCécile Henquell, Julien Guglielmini, Jannick Verbeeck, et al.
Gastroenterology|February 16, 2019
Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral TherapyDominique Thabut, Christophe Bureau, Richard Layese, et al.
Gut|October 30, 2015
Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)Pierre Nahon, Mathilde Lescat, Richard Layese, et al.
Gastroenterology|September 20, 2016
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver ComplicationsPierre Nahon, Valérie Bourcier, Richard Layese, et al.
Gastroenterology|May 6, 2018
Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort StudyCharlotte E Costentin, Richard Layese, Valérie Bourcier, et al.
Hepatology (Baltimore, Md.)|April 18, 2018
Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradicationManon Allaire, Pierre Nahon, Richard Layese, et al.
American Heart Journal|April 15, 2018
Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patientsPatrice Cacoub, Pierre Nahon, Richard Layese, et al.
BMC Public Health|July 19, 2022
LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countriesIsabel Graupera, Maja Thiele, Ann T Ma, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Hepatology (Baltimore, Md.)|June 28, 2016
Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir)Nathalie Ganne-Carrié, Richard Layese, Valérie Bourcier, et al.
Hepatology (Baltimore, Md.)|February 14, 2015
Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)Jean-Claude Trinchet, Valérie Bourcier, Cendrine Chaffaut, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|January 22, 2011
Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS studyCécile Henquell, Julien Guglielmini, Jannick Verbeeck, et al.
Gastroenterology|February 16, 2019
Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral TherapyDominique Thabut, Christophe Bureau, Richard Layese, et al.
Gut|October 30, 2015
Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)Pierre Nahon, Mathilde Lescat, Richard Layese, et al.
Gastroenterology|September 20, 2016
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver ComplicationsPierre Nahon, Valérie Bourcier, Richard Layese, et al.
Gastroenterology|May 6, 2018
Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort StudyCharlotte E Costentin, Richard Layese, Valérie Bourcier, et al.
Hepatology (Baltimore, Md.)|April 18, 2018
Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradicationManon Allaire, Pierre Nahon, Richard Layese, et al.
American Heart Journal|April 15, 2018
Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patientsPatrice Cacoub, Pierre Nahon, Richard Layese, et al.
BMC Public Health|July 19, 2022
LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countriesIsabel Graupera, Maja Thiele, Ann T Ma, et al.
Pageof 8